Clinical Trials Browser

Phase 1/2 × Terminated × Triple Negative Breast Neoplasms × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT06171789 2026-02-25

PRO1107 in Patients With Advanced Solid Tumors

Phase 1/2 Terminated

33 enrolled

BreastGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Phase 1/2 Terminated

73 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Sarcoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT02806258 2025-12-29

Néo-APBI-01

Phase 1/2 Terminated

362 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04725331 2025-11-21

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Phase 1/2 Terminated

31 enrolled

BreastDermatologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Sarcoma, Vaccinia, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03519178 2025-11-14

A Study of PF-06873600 in People With Cancer

Phase 1/2 Terminated

155 enrolled 44 charts

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT03838367 2025-09-09

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

Phase 1/2 Terminated

10 enrolled 15 charts

Breast

Triple Negative Breast Neoplasms

NCT03729596 2025-07-31

MGC018 With or Without MGA012 in Advanced Solid Tumors

Phase 1/2 Terminated

143 enrolled 33 charts

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04577963 2025-07-14

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/2 Terminated

52 enrolled 23 charts

BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Phase 1/2 Terminated

5 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03094169 2025-06-11

AVID100 in Advanced Epithelial Carcinomas

Phase 1/2 Terminated

49 enrolled 19 charts

BreastHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT06067061 2025-06-11

neoBREASTIM

Phase 1/2 Terminated

2 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04442126 2025-05-23

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Phase 1/2 Terminated

52 enrolled 33 charts

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05388435 2025-05-04

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Phase 1/2 Terminated

15 enrolled

BreastCNSThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Triple Negative Breast Neoplasms

NCT03829501 2025-04-02

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Phase 1/2 Terminated

222 enrolled 49 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Phase 1/2 Terminated

9 enrolled 18 charts

Breast

Triple Negative Breast Neoplasms

NCT02554812 2024-07-30

JAVELIN Medley

Phase 1/2 Terminated

409 enrolled 108 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03992131 2024-01-16

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Phase 1/2 Terminated

25 enrolled 11 charts

BreastGenitourinaryGynecologic

Carcinoma, Transitional Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04441099 2023-09-07

NBE-002 in Patients With Advanced Solid Tumors

Phase 1/2 Terminated

12 enrolled

BreastSarcoma

Carcinoma, Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03576131 2023-08-01

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

Phase 1/2 Terminated

48 enrolled 29 charts

BreastGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04424641 2023-07-25

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Phase 1/2 Terminated

48 enrolled 20 charts

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Prostatic Neoplasms, Uterine Neoplasms, Triple Negative Breast Neoplasms

NCT03435640 2023-03-08

REVEAL

Phase 1/2 Terminated

64 enrolled 22 charts

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Recurrence, Sarcoma, Colorectal Neoplasms, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05219578 2022-12-09

RTX-224 Monotherapy in Patients With Solid Tumors

Phase 1/2 Terminated

7 enrolled

BreastDermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Triple Negative Breast Neoplasms

NCT02457910 2022-08-22

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Phase 1/2 Terminated

30 enrolled 14 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Phase 1/2 Terminated

33 enrolled 14 charts

BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03277352 2021-07-22

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Phase 1/2 Terminated

10 enrolled 14 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02993094 2020-11-30

Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

Phase 1/2 Terminated

31 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02003092 2020-01-06

RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

Phase 1/2 Terminated

18 enrolled

Breast

Neoplasm Metastasis, Recurrence, Triple Negative Breast Neoplasms

NCT01939418 2017-10-03

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer

Phase 1/2 Terminated

23 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01918306 2017-06-27

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Phase 1/2 Terminated

11 enrolled 12 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

PRO1107 in Patients With Advanced Solid Tumors

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Néo-APBI-01

A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

A Study of PF-06873600 in People With Cancer

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

MGC018 With or Without MGA012 in Advanced Solid Tumors

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

AVID100 in Advanced Epithelial Carcinomas

neoBREASTIM

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

JAVELIN Medley

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

NBE-002 in Patients With Advanced Solid Tumors

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

REVEAL

RTX-224 Monotherapy in Patients With Solid Tumors

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer